DOCSLIB.ORG

Subject Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Subject Index 235 Subject Index A beta-catenin 166, 168 chemotherapy 155 bFGF 184 – adjuvant 155 ABCG2 97, 98 biliary tract tumor 125 – neoadjuvant 156 actinomycin D 91, 93, 114, 155, 156, 192 biopsy 72, 147, 223 chest X-ray 147 adenomatous polyposis coli 165 BK virus 7 chlonogenic tumor 90 adjuvant bladder rhabdomyosarcoma 124 chondroblastic osteosarcoma 221 – chemotherapy 155 bone chondrosarcoma 3, 47, 48 – radiotherapy 150, 152 –cancer3 chromosomal translocation 18, 182 adult respiratory distress syndrome – marrow aspirate 189 – 1p11-13 172 (ARDS) 125 – sarcoma 38, 39 – 2p24 108 AEWS0031 Protocol 190, 198 – tumor 72, 219 – 11p15 108 Affymetrix 24, 26 bone-seeking radioisotopes 220 – 2q35-36 172 Akt 210 bowel obstruction 126 – 12q13–15 108 Akt/TOR 97 brachytherapy 74, 153 – t(1;13) 106 ALK 140 brain metastases 148 – t(2;13) 91, 93, 106 – -1 144 BUN 222 – t(11;22) 145 alkylating agent 5, 120 busulfan 206 – t(17;22) 173 alopecia 74 – t(21;22) 188 alveolar – t(X;18) 141 – rhabdomyosarcoma 14, 91, 95, 105, – X;18 139 107, 114 C chromosome – soft part sarcoma 138 – 1 220 American Joint Committee calcification 37, 63 – 1q 188 on Cancer (AJCC) 149 camptothecin analogue 98 – 2p23 140 amputation 81, 150, 227 carboplatin 94 – 3q 220 aneurysmal bone cyst (ABC) 45 cardiomyopathy 158 – 8 188 angiomatoid MFH 169 cardiotoxicity 5, 125 – 9 220 angiosarcoma 135 caspase-8 210 – 10 220 ankylosing spondylitis 220 cataract 126 – 11 182 antifolate compound 228 CCG-7942 197 – 12 188 ARF 184 CD34 171, 174, 206 – 13 220 – transgenic 91 CD68 171, 175, 176 – 13q 220 ATM kinase 137 CD99 186 – 20 188 avian Rous sarcoma virus 135 CDK4 109, 184, 221 – 22 182 CDKN1A 108 – 17 220 CDKN2A 109 – 18q 220 B CDKNIC 108 – 117p 220 cervix 80 cisplatin 94, 225, 226 Beckwith-Wiedemann – lesion 124 c-KIT 15, 184 syndrome 9, 104 CESS 200 clathrin 140 benign – -81 76, 190, 202 clear cell sarcoma 136 – fibrohistiocytic tumor 176 – -86 76, 190, 202 – of tendons and aponeuroses 138 – fibrous histiocytoma 170 CGH 20, 108, 138 clinical staging 149 236 Subject Index clinical trial phase II 89 E EWS-FLI1 186, 188, 190, 210, 211 CLTC 144 EWS-WT1 136 Codman’s triangle 44 E1AF 182 excision COG 226–228 EBMTR 204, 206 – en bloc 227 COL1A1 140, 173 ecteinascidin-743 157, 209 – intracapsular 176 colonic polyp 165 EICESS 191, 200, 205 – marginal 176 color Doppler flow imaging (CDFI) 42 – -92 76 – wide local 176 congenital fibrosarcoma 62 ejaculatory problem 126 exon 183 conjunctivitis 126 electron 73 external beam radiation therapy continuation therapy 192 – microscopy 16 (XRT) 73, 154 COSS 226, 227 embryonal extraosseous osteosarcoma 221 Costello syndrome 9, 104 – rhabdomyosarcoma 14, 108 extraskeletal myxoid chondor- creatinine 222 – – botryoid variant 105 sarcoma 138 CT 37, 39, 40, 43, 48, 54, 111, 116, 147, – – spindle cell variant 105 extremity 80 152, 222, 223 – tumor 107 – tumor 110, 123 – of the chest 222 en bloc excision 227 ezrin 224 cutaneous endometrial stromal sarcoma 138 – ESFT 189 endoprosthetic replacement 225 F – fibrohistiocytic soft tissue tumor 170 EOI 227 CWS-86 79 epirubicin 156 cyclo-oxygenase inhibitor 168 factor XIIIa 171, 174, 175 epithelial membrane antigen familial adenomatous polyposis 166 cyclophosphamide 91, 92, 114, (EMA) 141 fat spin echo (FSE) 38 120–122, 155, 156, 192, 197, 208 erbB-2 224 female genital tract tumor 123 – dose intensification 127 ERG 188 cytokeratin 141 FEV 182 ESFT, see Ewing’s sarcoma family fever 189 cytotoxic T lymphocyte 211 of tumors FGF 137 esophagitis 116 fibroblastic etoposide 121, 127, 190, 192, 197, 202, D – myofibroblastic tumor 1767 205, 225 – osteosarcoma 221 ETV1 182 dacarbazine 155 – tumor 170 ETV6-NTRK3 139 deep fibromatosis 166–168 fibrohistiocytic tumor 164, 169, 170 EURAMOS 227 DEMRI 41–43 fibromatosis 164, 166, 168 EURO-EWING 99 Protocol 198–200, dermatofibroma 170, 171 fibrosarcoma 63, 82, 134, 135, 155, 174 204 dermatofibrosarcoma 134 – adult type 143 EWI-92 195 – protuberans 138, 140, 173, 174, 176 fibrous histiocytoma 171 Ewing’s sarcoma 1, 3, 39, 40, 48–50, 75, desmin 106 fine needle aspiration 147 146 desmoid tumor 51, 52, 60, 167 FISH 13, 18, 138, 186, 188 – extraosseous 182 desmoplastic small round cell tumor FKHR 107 – family of tumors (ESFT) 52, 53, 181, (DSRCT) 54, 82, 136, 138, 145 FLI1 184, 188 182, 184, 185, 190–192, 195, 199–203, dexrazoxane 158 – exon 5 187 207, 210 distant metastases 151 – exon 6 187 – – cutaneous 189 DNA fluoride 6 – – extraosseous 189 – ligase IV 137 fluorine-18-fluorodeoxyglucose – – face 189 – microarray 23 positron emission tomography – – primary sites 188 – polyomavirus 221 (18-FDG PET) 38–40, 42, 43 docetaxel 157 ––recurrent208 fluoroscopy 43 dose response 195 – – subcutaneous 189 French Federation of Cancer Centers doxorubicin 93, 120, 21, 127, 155, 156, – pathology 185 Sarcoma Group (FNCLCC) 150 192, 197, 202, 225, 226 EWS 145, 184 drug resistance 90 – exon 7 187 Dupuytren’s contracture 164 EWS/ETS 182 G DVM 42 EWS/FLI1 183 dynamic enhanced MR imaging EWS-ATF1 136 gastrointestinal stromal tumor 15, (DEMRI) 38 EWS-CHOP 136 140, 144 dystrophic calcification 141 EWS-ERG 188, 190 G-CSF 40, 195, 199 Subject Index 237 GD2 228 IGF – -IV 79, 112, 114, 117, 120, 122, 123 gefitinib 97 – -1 184, 210 ––pilot114 gemcitabine 157, 228 – -1R 184, 210 – -V 112, 115, 120 gene marking 206 – -2 108, 184 isolated limb perfusion 157 genomic instability 137 IL-2 206 giant cell image-guided ablation 37 J – fibroblastoma 173, 174, 177 imatinib 97, 98 – tumor 45 – mesylate 144, 158, 177, 209 JC virus 7 – – diffuse type 172 immunohistochemical stain 13 joint arthrodeses 83 – – of soft tissue 175, 176 immunohistochemistry 15 juvenile xanthogranuloma 170, 171, 176 – – of tendon sheath 172, 173 IMRT 79 Gleevec 24 IMT 140 gradient echo (GE) 38 induction chemotherapy 192, 223 K grading system 146 infantile – fibrosarcoma 134, 135, 138, 139, 142, Kaposi’s sarcoma 135 146 H karyotyping 13 – hemangiopericytoma 134, 135, 145, – spectral 19 146 keratin 142 H19 108 inflammatory myofibroblastic keratitis 126 HAM56 171 tumor 138, 140, 144 KIT 140, 144 HDM2 137 INI1 139, 143 head and neck non-orbital tumor 122 INK4A 184 hearing acuity 126 – transgenic 91 L height velocity 126 Ink4a/Arf gene locus 137 hemangioma 51, 60 inorganic arsenic 135 Langerhans cell histiocytosis 45 hemangiopericytoma 63–65 in-situ hybridization 18 LDH 189, 190, 222, 224 hematoxylin and eosin (H&E) insulin-like growth factor 184 learning disability 126 staining 13, 14 INT-0091 195 Ledderhose disease 164 hemorrhagic cystitis 158 intensity modulated radiation therapy leiomyosarcoma 155, 158 hepatopathy 126 (IMRT) 74, 116, 154 leucovorin 225 HER2 224, 228 interferon 168 Li-Fraumeni syndrome 5, 104, 220 hereditary retinoblastoma 5 Intergroup Ewing’s Sarcoma limb-sparing surgery 150, 227 hernia 6 Study 76 liposarcoma 155 HGF 109 Intergroup Rhabdomyosarcoma local – transgenic 91 –control71 Study (IRSG) 104, 149 hierarchical clustering 26 – failure 202 International Classification histone deacetylation 209 – radiation 200 of Rhabdomyosarcoma 105 HIV testing 222 – therapy 200 International Union Against HLA 207 low-grade fibromyxoid sarcoma 138 Cancer (UICC) 149 hormone replacement 126 LRP5 224 intra-abdominal tumor 111 HSCT 205 lung intracapsular excision 176 human – metastases 204 intraoperative radiation therapy – herpesvirus-8 135 – radiation therapy 152 (IORT) 74 – immunodeficiency virus 1 135 lymph node 82 ionizing radiation 135 hydronephrosis 126 – sampling 111 ipsilateral nerve sparing resection hyperfractionated RG 115 lymphangiosarcoma 135 of spermatic vessels and nodes 111 HyperME 206 lymphedema 126 Iressa 24 hypoplasia 126 lymphoscintigraphy 40 irinotecan 94, 95, 97, 127, 209 irridiation 220 I IRSG 77 M – grouping system 111 ICAR 42 – -I 111, 115, 117, 121 M1B-1 labeling index 171 IE 195, 199, 203 – -II 112, 115, 117, 121–123 MAC387 171 ifosfamide 120, 121, 127, 155, 156, 190, – -III 111, 112, 114, 115, 117, 121, 122, malignant fibrous histiocytoma (MFH) 192, 197, 202, 225, 226 123 46, 47, 62, 134, 135, 155, 158 238 Subject Index malignant peripheral nerve sheath myogenin 93, 106 p16Ink4 137 tumor (MPNST) 65, 134, 135, 142, myoglobin 106 p21Waf/Cip1 137 155, 158 myxofibrosarcoma 169 p53 5, 8, 91, 108, 134, 137, 184, 194, 220, MAPK 184, 210 myxoid liposarcoma 136, 138 222 marginal local excision 176 myxoid MFH 169 – staining 171 matrix Paget’s disease 219–221 –analysis26 parameningeal rhabdomyo- – metalloproteinase inhibitor 168 N sarcoma 79 MDM2 108, 184 parameningeal tumor 121 mdm2 221 nausea 74 paratesticular rhabdomyo- MDR-1 224 NCI screening program 90 sarcoma 80, 123 ME 42 necrosis 223–225 parental smoking 7 melphalan 121, 127, 205, 206 neoadjuvant chemotherapy 156 parotid tumor 122 Memorial Sloan-Kettering Cancer neuroblastoma 94, 146 partial cystectomy 80 Center (MSKCC) 149, 197, 202 neurofibroma 136 PAS 186 mesenchymal cell 136, 181 neurofibromatosis 171 PAX3 106 metastases 203 – type 1 (NF-1) 8, 65, 105, 135, 137, 138 – FKHR 91, 107 – bone 222 neurosecretory granules 16 PAX7 106 – brain 148 nodular tenosynovitis 172 – FKHR 107 – distant 151 non-parameningeal tumor 122 PCR 13, 17, 20, 206 – lung 204 non-rhabdomyosarcoma soft-tissue PDGF 140 – pulmonary 147 sarcoma (NRSTS) 39, 61, 75, 81, 82, – α 144 – skeleton 222 134, 135, 138, 147 – -B 140, 173 metastatic disease 114, 121, 146, 190, – clinical staging 149 Pediatric Oncology Group 222, 223 – prognostic factors 148 (POG) 135, 150 methotrexate 225, 226 Pediatric Oncology Preclinical MHC 207 O Protein Array Project MIC2 186 (POPP-TAP) 91 microarray 13, 24, 107 oligonucleotide array 24 Pediatric Preclinical Testing Program
Load more

Recommended publications
  • The Best Diagnosis Is: A
    DErmatopathology Diagnosis The best diagnosis is: a. eruptive xanthomacopy H&E, original magnification ×200. b. juvenile xanthogranuloma c. Langerhans cell histiocytosis d. reticulohistiocytomanot e. Rosai-Dorfman disease Do CUTIS H&E, original magnification ×600. PLEASE TURN TO PAGE 39 FOR DERMATOPATHOLOGY DIAGNOSIS DISCUSSION Alyssa Miceli, DO; Nathan Cleaver, DO; Amy Spizuoco, DO Dr. Miceli is from the College of Osteopathic Medicine, New York Institute of Technology, Old Westbury. Drs. Cleaver and Spizuoco are from Ackerman Academy of Dermatopathology, New York, New York. The authors report no conflict of interest. Correspondence: Amy Spizuoco, DO, Ackerman Academy of Dermatopathology, 145 E 32nd Street, 10th Floor, New York, NY 10016 ([email protected]). 16 CUTIS® WWW.CUTIS.COM Copyright Cutis 2015. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. Dermatopathology Diagnosis Discussion rosai-Dorfman Disease osai-Dorfman disease (RDD), also known as negative staining for CD1a on immunohistochemis- sinus histiocytosis with massive lymphade- try. Lymphocytes and plasma cells often are admixed nopathy, is a rare benign histioproliferative with the Rosai-Dorfman cells, and neutrophils and R 1 4 disorder of unknown etiology. Clinically, it is most eosinophils also may be present in the infiltrate. frequently characterized by massive painless cervical The histologic hallmark of RDD is emperipolesis, lymphadenopathy with other systemic manifesta- a phenomenon whereby inflammatory cells such as tions, including fever, night sweats, and weight loss. lymphocytes and plasma cells reside intact within Accompanying laboratory findings include leukocyto- the cytoplasm of histiocytes (Figure 2).5 sis with neutrophilia, elevated erythrocyte sedimenta- The histologic differential diagnosis of cutaneous tion rate, and polyclonal hypergammaglobulinemia.
    [Show full text]
  • Lesmono Bayu, Dewi Yussy Afriani, Ratunanda Sinta Sari, Aroeman Nur Akbar
    Necrobiotic Xanthogranuloma Sucessfully Treated with Cyclosphospamide-Methyl Prednisolon Lesmono Bayu, Dewi Yussy Afriani, Ratunanda Sinta Sari, Aroeman Nur Akbar Departement of Otorhinolaryngology Head and Neck Surgery Faculty of Medicine Padjadjaran University-Dr. Hasan Sadikin General Hospital Bandung ABSTRACT Objective: Necrobiotic Xanthogranuloma (NXG) is a rare, chronic, and progressive disease that provokes skin lesions, such as damage of the histiocytes of Non-Langerhans cell, skin lesions (yellowish or noduled ulcerative lesions) in the induration skin. The most common predilection areas are on the face, orbital, and extremities. The etiology is still unknown, but sometimes is often associated with monoclonal gammopathy. The granulomatous infiltrate was composed of lymphocytes, epithelioid cells, foamy histiocytes and giant cells, many of them of Touton type. Some patients who had lesions are asymptomatic, sometimes they will feel paresthesias, burning pain. Nowadays, this management still vary widely, include medicamentous (cytostatics, steroids), radiotherapy, and surgery. Sets forth the results of two patients NXG. Methods: The subjects in this study were a 44-years-old male patient with some lesions on both cheeks and forehead since 5 months ago and a 29-years-old female patient with some lesions on both cheeks and ears. Results: First patient treated with Methylprednisolon 0.8 mg/Kg and tappered off for a month with improved results. Second patient treated with Cyclosphosphamide 750 mg/m2 with improved results within three weeks. Conclusion: Necrobiotic Xanthogranuloma treatment still required further research by the number of samples that much to find out the efficiency management NXG. Keywords: Cyclosphosphamide, methylprednisolon, necrobiotic xanthogranuloma 1 Introduction Necrobiotic Xanthogranuloma (NXG) is a rare disease, a chronic, progressive and cause skin lesions in the form of damage to the cell Non-Lagerhans histiocytes.
    [Show full text]
  • An Unusual Juvenile Xanthogranuloma on a Finger MCP Joint
    200 An Unusual Juvenile Xanthogranuloma on a Finger MCP Joint Sang Hee Cha, M.D., Sang Hyun Cho, M.D., Jeong Deuk Lee, M.D. Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea Juvenile xanthogranuloma (JXG) is a benign self-limited histiocytic proliferative disorder that usually occurs in early childhood. JXG appears as reddish to yellow, papules, or nodules, and although the head, neck, and trunk are the most frequent locations, it can occur at any body site. However, JXG involving the finger is rare. Histologically, JXG is characterized by an ill-defined, unencapsulated, dense histiocytic infiltrate within the dermis, some of which is contained in Touton giant cells, foreign body giant cells and foamy cells. Because the cutaneous lesions spontaneously regress, treatment is not usually indicated. The authors report a case of JXG in a 4-year-old girl who had tender, yellowish papule on the ventral aspect of the MCP joint of the right fourth finger consistent with JXG. (Ann Dermatol (Seoul) 20(4) 200∼203, 2008) Key Words: Finger, Juvenile xanthogranuloma INTRODUCTION CASE REPORT Juvenile xanthogranuloma (JXG) is a benign A 4-year-old girl presented with a papule of cutaneous histiocytic proliferation, and was first several months duration on the ventral aspect of described by Helwig and Hackney in 19541. The the right fourth finger MCP joint (Fig. 1). The pathophysiology of JXG is not well understood, lesion was a firm, dome-shaped, yellowish, 0.4×0.4 although it is thought to originate from a histiocytic cm sized papule. There was no remarkable past or granulomatous reaction2,3.
    [Show full text]
  • Cutaneous Disseminated Xanthogranuloma in an Adult: Case Report and Review of the Literature
    CONTINUING MEDICAL EDUCATION Cutaneous Disseminated Xanthogranuloma in an Adult: Case Report and Review of the Literature Adam Asarch, BA; Jens J. Thiele, MD, PhD; Harty Ashby-Richardson, DO; Pamela S. Norden, MD, MBA RELEASE DATE: May 2009 TERMINATION DATE: May 2010 The estimated time to complete this activity is 1 hour. GOAL To understand xanthogranuloma (XG) to better manage patients with the condition LEARNING OBJECTIVES Upon completion of this activity, you will be able to: 1. Describe the clinical, histologic, and immunohistochemical characteristics of XG. 2. Distinguish XG from other xanthomatous disorders. 3. Summarize pathogenic mechanisms of XG. INTENDED AUDIENCE This CME activity is designed for dermatologists and generalists. CME Test and Instructions on page 263. This article has been peer reviewed and approved Einstein College of Medicine is accredited by by Michael Fisher, MD, Professor of Medicine, the ACCME to provide continuing medical edu- Albert Einstein College of Medicine. Review date: cation for physicians. April 2009. Albert Einstein College of Medicine designates This activity has been planned and imple- this educational activity for a maximum of 1 AMA mented in accordance with the Essential Areas PRA Category 1 Credit TM. Physicians should only and Policies of the Accreditation Council for claim credit commensurate with the extent of their Continuing Medical Education through the participation in the activity. joint sponsorship of Albert Einstein College of This activity has been planned and produced in Medicine and Quadrant HealthCom, Inc. Albert accordance with ACCME Essentials. Mr. Asarch and Drs. Ashby-Richardson and Norden report no conflict of interest. Dr. Thiele is a consultant for Colgate-Palmolive Company.
    [Show full text]
  • Coexistence of Juvenile Xanthogranuloma And
    Vol.36 No.1 Case report 25 Coexistence of juvenile xanthogranuloma and diffuse plane xanthoma in 22-month- old boy could potentially be caused by digenic inheritance of APOB and APOE4 polymorphism Kamonrat Sunantawanich MD, Niorn Boonpuen MD, Narumon Densupsoontorn MD, Vip Viprakasit MD PhD, Pimpa Tantanasrigul MD, Poonnawis Sudtikoonaseth MD, Vesarat Wessagowit MD, PhD. ABSTRACT: SUNANTAWANICH K*, BOONPUEN N*, DENSUPSOONTORN N**, VIPRAKASIT V**, TANTANASRIGUL P*, SUDTIKOONASETH P*, WESSAGOWIT V*. COEXISTENCE OF JUVENILE XANTHOGRANULOMA AND DIFFUSE PLANE XANTHOMA IN 22-MONTH-OLD BOY COULD POTENTIALLY BE CAUSED BY DIGENIC INHERITANCE OF APOB AND APOE4 POLYMORPHISM. THAI J DERMATOL 2020; 36: 25-30. *INSTITUTE OF DERMATOLOGY, DEPARTMENT OF MEDICAL SERVICES, MINISTRY OF PUBLIC HEALTH, BANGKOK, THAILAND. **DEPARTMENT OF PEDIATRICSFACULTY OF MEDICINE SIRIRAJ HOSPITAL, BANGKOK, THAILAND. From: Institute of Dermatology, Department of Medical Services, Ministry of Public Health, Bangkok, Thailand Corresponding author: Niorn Boonpuen MD, email: [email protected] Received: 10 October 2019 Revised: 25 November 2019 Accepted: 25 December 2019 26 Sunantawanich K, et al. Thai J Dermatol, January-March, 2020 The coexistence of juvenile xanthogranuloma and diffuse plane xanthoma is considered a rare phenomenon. We report a 22-month-old boy with multiple orange-tan papules and yellow plaques on his entire body for 18 months. Two types of histological findings confirmed the diagnosis of juvenile xanthogranuloma and plane xanthoma, respectively. Additionally, the patient’s blood test showed high cholesterol level, which could be associated with familial or secondary dyslipidemia. Key words: Juvenile xanthogranuloma, diffuse plane xanthoma, pediatric, dyslipidemia Introduction lesions on his face. The lesions had gradually Juvenile xanthogranuloma (JXG) is the most increased in size and number.
    [Show full text]
  • Emperipolesis in a Juvenile Xanthogranuloma: Sentinel Case Report and Review of the Literature
    Case Report Annals of Clinical Case Reports Published: 26 Nov, 2018 Emperipolesis in a Juvenile Xanthogranuloma: Sentinel Case Report and Review of the Literature Kurt J Knowles1*, Shoujun Chen1, Kathryn Rhymes2, Kevin Boykin2 and Ailing Li1 1Department of Pathology and Translational Pathobiology, LSU Health Science Center Shreveport, USA 2Department of Pediatric Surgery, LSU Health Science Center enter Shreveport, USA Abstract This is the first reported case of a giant juvenile xanthogranuloma with multiple unusual features. The patient is an infant who presented with a rapidly growing 4.0 cm soft tissue mass on the back with necrosis and ulceration. MRI demonstrated the characteristic signaling of sebaceous cyst. Histology revealed a large and well-circumscribed dermal lesion that is composed predominately of histiocytes, lymphocytes, eosinophils, multinucleated giant cells, Touton giant cells and the extremely unique feature consisting of an extraordinarily high degree of emperipolesis. The diagnosis of juvenile xanthogranuloma is confirmed by positive immunostaining for CD68 and CD163, and negative immunostaining for CD1a, CD117 and S100 ruled out a Langerhans cell lesion. The final diagnosis is giant juvenile xanthogranuloma with emperipolesis simulating Rosai-Dorfman Disease, a lesion that has never been reported, and may represent a mixture of a dendritic cell related tumor and a macrophage related tumor according to the 1997 WHO classification of histiocytic lesions. Keywords: Xanthogranuloma; Juvenile; Emperipolesis; Non-Langerhans cell histiocytosis Introduction Juvenile Xanthogranuloma (JXG) is a non-Langerhans histiocytic proliferative disorder most common in infancy or childhood although cases in adult and elderly patients have been reported OPEN ACCESS [1,2]. JXG presents with one or more cutaneous or subcutaneous nodules often occurring in head *Correspondence: and neck but also on trunk and extremities.
    [Show full text]
  • Adult-Onset Juvenile Xanthogranuloma of the External Auditory Canal: a Case Report 성인에서 발생한 외이도의 소아 황색 육아종: 증례 보고
    Case Report pISSN 1738-2637 / eISSN 2288-2928 J Korean Soc Radiol 2016;74(5):335-338 http://dx.doi.org/10.3348/jksr.2016.74.5.335 Adult-Onset Juvenile Xanthogranuloma of the External Auditory Canal: A Case Report 성인에서 발생한 외이도의 소아 황색 육아종: 증례 보고 Joonho Hur, MD1, Jae Kyun Kim, MD1,2*, Nara Kim, MD3, Giyoung Seo, MD1, Woosun Choi, MD1, Jun Soo Byun, MD1, Woong Jae Lee, MD1, Tae Jin Lee, MD4 Departments of 1Radiology, 4Pathology, Chung-Ang University College of Medicine, Chung-Ang University Hospital, Seoul, Korea 2Department of Radiology, Kangwon National University College of Medicine, Chuncheon, Korea 3Department of Radiology, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea Juvenile xanthogranuloma (JXG) is a benign, spontaneously regressing lesion that usually occurs during the first year of life, but may also occur in adulthood. Although Received June 13, 2014 the most common presentation of JXG is the cutaneous lesion, it can also manifest Revised February 16, 2015 Accepted September 16, 2015 in various visceral organs. JXG of the external auditory canal is extremely rare, and *Corresponding author: Jae Kyun Kim, MD there have been only a few reports of those cases in the English literature. In this Department of Radiology, Chung-Ang University College of Medicine, Chung-Ang University Hospital, study, we present a case of pathologically proven JXG that occurred in the external 102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea. auditory canal with a symptomatic clinical presentation. Tel. 82-2-6299-2662 Fax. 82-2-6263-1557 E-mail: [email protected] Index terms This is an Open Access article distributed under the terms Xanthogranuloma, Juvenile of the Creative Commons Attribution Non-Commercial Ear Canal License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distri- Tomography, X-Ray Computed bution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • Emtree Terms Added and Changed (January 2021)
    Emtree terms added and changed (January 2021) This is an overview of new terms added and changes made in the first Emtree release in 2021. Overall, Emtree has grown by 1,617 preferred terms (457 drug terms and 1,198 non-drug terms) compared with the previous version released in September 2020. In total Emtree now counts 88,945 preferred terms. Because the terms added include replacements for existing preferred terms (which become synonyms of the new terms) as well as completely new concepts, the number of terms added exceeds the net growth in Emtree. Other changes could include the merging of two or more existing preferred terms into a single concept. The terms added and changed are summarized below and specified in detail on the following pages. Emtree terms added in January 2021 1,695 new terms (including 78 replacement terms and promoted synonyms) have been added to Emtree as preferred terms in version January 2021 (compared to September 2021): 457 drug terms (terms assigned to the Chemicals and Drugs facet). 1,238 non-drug terms (terms not assigned as Chemicals and Drugs). The new terms (including the replacement terms and the promoted synonyms) are listed as Terms added on the following pages. Note that many of these terms will have been indexed prior to 2021 (typically as candidate terms), sometimes for several years, before they were added to Emtree. Emtree terms changed in January 2021 87 terms (38 drug terms and 40 non-drug terms) from Emtree September 2020 have been replaced by 78 different terms in January 2021 (38 drug terms and 40 non-drug terms).
    [Show full text]
  • Jennifer a Cafardi the Manual of Dermatology 2012
    The Manual of Dermatology Jennifer A. Cafardi The Manual of Dermatology Jennifer A. Cafardi, MD, FAAD Assistant Professor of Dermatology University of Alabama at Birmingham Birmingham, Alabama, USA [email protected] ISBN 978-1-4614-0937-3 e-ISBN 978-1-4614-0938-0 DOI 10.1007/978-1-4614-0938-0 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2011940426 © Springer Science+Business Media, LLC 2012 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identifi ed as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) Notice Dermatology is an evolving fi eld of medicine.
    [Show full text]
  • Common Signalling Pathways in Macrophage and Osteoclast Multinucleation
    Common signalling pathways in macrophage and osteoclast multinucleation Marie Pereira1, Enrico Petretto2, Siamon Gordon3,4, J. H. Duncan Bassett5, Graham R. Williams5, Jacques Behmoaras1 1 Centre for Inflammatory Disease, Imperial College London, W12, 0NN, London, UK 2 Duke-NUS Medical School, Singapore 169857, Republic of Singapore 3 Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan City33302, Taiwan 4 Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE UK 5 Molecular Endocrinology Laboratory, Department of Medicine, Imperial College London, London, UK Abstract Macrophage cell fusion and multinucleation are fundamental processes in the formation of multinucleated giant cells (MGCs) in chronic inflammatory disease and osteoclasts in the regulation of bone mass. However, this basic cell phenomenon is poorly understood despite its pathophysiological relevance. Granulomas containing multinucleated giant cells are seen in a wide variety of complex inflammatory disorders, as well as in infectious diseases. Dysregulation of osteoclastic bone resorption underlies the pathogenesis of osteoporosis and malignant osteolytic bone disease. Recent reports have shown that the formation of multinucleated giant cells and osteoclast fusion display a common molecular signature, suggesting shared genetic determinants. In this Review, we describe the background of cell- cell fusion and the similar origin of macrophages and osteoclasts. We specifically focus on the common pathways involved in osteoclast and MGC fusion. We also highlight potential approaches that could help to unravel the core mechanisms underlying bone and granulomatous disorders in humans. ~ 1 ~ Introduction The fusion of plasma membranes is an active, frequent and universal phenomenon in living cells. Here, two forms of fusion can be distinguished as they lead to functionally diverse cell activities.
    [Show full text]
  • Benacka, MD, Phd Department of Pathophysiology Medical Faculty, Safarik University , Košice
    Academic lectures for general medicine GENERAL Summer course 3rd year PATHOPHYSIOLOGY Updated 2001- 2016 CHRONIC INFLAMMATION R. A- Benacka, MD, PhD Department of Pathophysiology Medical faculty, Safarik University , Košice Figures and tables in this presentation were adapted from various printed and electronic resorces and serve strictly for educational purposes. Characteristics Definition: duration: inflammatory disease lasting more than 6-8 weeks ; or recurrently for 2 consecutive y. ; subacute inflam. (2-8 w) a) continuation of acute, through subacute inflammations b) recurrent bounces of inflammation c) chronic inflammation of „low intensity“ w/o acute stage histology: always lack of Neu; predominance of Mo/Mf, T- lymphocytes, maybe Ba, Eo; plasmatic cells, fibroblasts, smooth muscle cells ; Non specific : gastric ulcer ; Specific : granuloma s - special cells (epithelioid, giant cells - Langhans, foamy cells, etc.) Pathology vs acute inflammation: Less prominent vascular changes (induration instead of swelling, little Time (2004): Chronic inflammation “The Secret Killer” redness), more visible fibrotic changes (extracellul. matrix); Viscous circle – destruction vs. reparation perpetuate concurrently instead of consequently scars, Tissue alteration is prominent Exagerated mitotic activity - neoangiogenesis, connective tissue; cellularisation, cell transformation may occur - dysplasias, metaplasias, anaplasias ... Certain chronic inflammations lead to neoplasias. Dr. Barry Marshall, Dr. Robin Warren H. Pylori Nobel Prize for
    [Show full text]
  • Ocular Pathology Review © 2015 Ralph C. Eagle, Jr., M.D. Director, Department of Pathology, Wills Eye Hospital 840 Walnut Stree
    Ocular Pathology Review © 2015 Ralph C. Eagle, Jr., M.D. Director, Department Of Pathology, Wills Eye Hospital 840 Walnut Street, Suite 1410, Philadelphia, Pennsylvania 19107 (revised 12/26/2015) [email protected] INFLAMMATION A reaction of the microcirculation characterized by movement of fluid and white blood cells from the blood into extravascular tissues. This is frequently an expression of the host's attempt to localize and eliminate metabolically altered cells, foreign particles, microorganisms or antigens Cardinal manifestions of Inflammation, i.e. redness, heat, pain and diminished function reflect increases vascular permeability, movement of fluid into extracellular space and effect of inflammatory mediators. Categories of Inflammation- Classified by type of cells in tissue or exudate Acute (exudative) Polymorphonuclear leukocytes Mast cells and eosinophils Chronic (proliferative) Nongranulomatous Lymphocytes and plasma cells Granulomatous Epithelioid histiocytes, giant cells Inflammatory Cells Polymorphonuclear leukocyte Primary cell in acute inflammation (polys = pus) Multilobed nucleus, pink cytoplasm First line of cellular defense Phagocytizes bacteria and foreign material Digestive enzymes can destroy ocular tissues (e.g. retina) Abscess: a focal collection of polys Suppurative inflammation: numerous polys and tissue destruction (pus) Endophthalmitis: Definitions: Endophthalmitis: An inflammation of one or more ocular coats and adjacent cavities. Sclera not involved. Clinically, usually connotes vitreous involvement. Panophthalmitis:
    [Show full text]